COMP <GO>
EWTX vs ARQT // 10Y YIELD & FRED MACRO BETA
Edgewise Therapeutics Inc. (NASDAQ) VS. Arcutis Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EWTX 4
— ARQT 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: EWTX
LAST: $38.90 (-0.03%) • MKT CAP: $4.22B
macro-sensitivity
1.10
LAST: $32.07 (+0.31%) • MKT CAP: $4.03B
macro-sensitivity
1.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. ARQT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | ARQT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 90.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | -3.00% | -28.90 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | -0.16% | -3.25 | ARQT | /fcf-yield <GO> |
| Operating Margin | -16.20% | -3.30% | -12.90 | ARQT | /operating-margins <GO> |
| Net Profit Margin | 0.00% | -4.30% | +4.30 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 91.30% | -92.40 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 7.78 | +18.22 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 6/9 | -3.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 66.0 | -20.30 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.10 | 1.00 | +0.10 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 24.0x | +1.00 | ARQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $4.03B | $193.8M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | ARQT REV | EWTX GROSS % | ARQT GROSS % | EWTX FCF | ARQT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $376.1M | — | 90.2% | -$144.1M | -$6.3M |
| FY 2024 | $0 | $196.5M | — | 90.3% | -$110.3M | -$112.3M |
| FY 2023 | $0 | $59.6M | — | — | -$91.9M | -$249.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
ARQT // BETA 1.00